GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FIT Biotech Oy (OHEL:FITBIO) » Definitions » FCF Margin %

FIT Biotech Oy (OHEL:FITBIO) FCF Margin % : 0.00% (As of Jun. 2018)


View and export this data going back to 2015. Start your Free Trial

What is FIT Biotech Oy FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. FIT Biotech Oy's Free Cash Flow for the six months ended in Jun. 2018 was €-1.90 Mil. FIT Biotech Oy's Revenue for the six months ended in Jun. 2018 was €0.00 Mil. Therefore, FIT Biotech Oy's FCF Margin % for the quarter that ended in Jun. 2018 was 0.00%.

As of today, FIT Biotech Oy's current FCF Yield % is -707.99%.

The historical rank and industry rank for FIT Biotech Oy's FCF Margin % or its related term are showing as below:

OHEL:FITBIO' s FCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -27950


OHEL:FITBIO's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -138.52 vs OHEL:FITBIO: -27950.00


FIT Biotech Oy FCF Margin % Historical Data

The historical data trend for FIT Biotech Oy's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FIT Biotech Oy FCF Margin % Chart

FIT Biotech Oy Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
FCF Margin %
-1,332.23 -5,096.67 -13,015.00 -26,490.00 -

FIT Biotech Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18
FCF Margin % Get a 7-Day Free Trial Premium Member Only -13,230.00 - - - -

Competitive Comparison of FIT Biotech Oy's FCF Margin %

For the Biotechnology subindustry, FIT Biotech Oy's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FIT Biotech Oy's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FIT Biotech Oy's FCF Margin % distribution charts can be found below:

* The bar in red indicates where FIT Biotech Oy's FCF Margin % falls into.



FIT Biotech Oy FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

FIT Biotech Oy's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=-2.558/0
= %

FIT Biotech Oy's FCF Margin for the quarter that ended in Jun. 2018 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2018 )/Revenue (Q: Jun. 2018 )
=-1.895/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FIT Biotech Oy FCF Margin % Related Terms

Thank you for viewing the detailed overview of FIT Biotech Oy's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


FIT Biotech Oy (OHEL:FITBIO) Business Description

Traded in Other Exchanges
N/A
Address
Biokatu 12, Tampere, FIN, FI-33520
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.

FIT Biotech Oy (OHEL:FITBIO) Headlines

No Headlines